Electrocore (ECOR) vs. Its Competitors Head to Head Contrast

Share on StockTwits

Electrocore (NASDAQ: ECOR) is one of 47 public companies in the “Electromedical equipment” industry, but how does it contrast to its rivals? We will compare Electrocore to related companies based on the strength of its dividends, valuation, earnings, profitability, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Electrocore and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Electrocore 0 0 3 0 3.00
Electrocore Competitors 217 639 1232 58 2.53

Electrocore currently has a consensus target price of $21.50, suggesting a potential upside of 266.89%. As a group, “Electromedical equipment” companies have a potential upside of 29.22%. Given Electrocore’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Electrocore is more favorable than its rivals.

Profitability

This table compares Electrocore and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Electrocore N/A N/A N/A
Electrocore Competitors -126.75% -53.56% -20.00%

Institutional and Insider Ownership

14.5% of Electrocore shares are owned by institutional investors. Comparatively, 48.3% of shares of all “Electromedical equipment” companies are owned by institutional investors. 15.3% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Electrocore and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Electrocore $990,000.00 -$55.82 million -4.92
Electrocore Competitors $1.19 billion $88.54 million 16.73

Electrocore’s rivals have higher revenue and earnings than Electrocore. Electrocore is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Electrocore Company Profile

electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

Receive News & Ratings for Electrocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electrocore and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bloomin’ Brands Inc to Post Q1 2019 Earnings of $0.72 Per Share, William Blair Forecasts
Bloomin’ Brands Inc to Post Q1 2019 Earnings of $0.72 Per Share, William Blair Forecasts
Q1 2019 Earnings Forecast for Precision BioSciences Issued By Jefferies Financial Group
Q1 2019 Earnings Forecast for Precision BioSciences Issued By Jefferies Financial Group
Trivago  Upgraded at Guggenheim
Trivago Upgraded at Guggenheim
LYFT  Receives New Coverage from Analysts at Canaccord Genuity
LYFT Receives New Coverage from Analysts at Canaccord Genuity
Broadcom Inc  Stake Lowered by Duff & Phelps Investment Management Co.
Broadcom Inc Stake Lowered by Duff & Phelps Investment Management Co.
Owens Corning  Expected to Post Q1 2019 Earnings of $0.61 Per Share
Owens Corning Expected to Post Q1 2019 Earnings of $0.61 Per Share


© 2006-2019 Ticker Report